Search results
- “As the global market leader in pulmonary fibrosis, we have the ambition to go beyond slowing down disease progression and hope to one day provide a cure for this chronic debilitating condition,” said Carinne Brouillon, Member of the Board of Managing Directors and Head of Human Pharma, Boehringer Ingelheim.
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis at Boehringer Ingelheim, discusses the unmet needs of patients with IPF and other forms of progressive fibrosing ILDs and the FIBRONEER™ global clinical program
- Boehringer Ingelheim’s latest investigational treatment ...
Potential new treatment for progressive pulmonary fibrosis...
- FIBRONEER Ph3 trials in patients with IPF and other PF-ILD
Donald Zoz, M.D., Director and Senior Clinical Program...
- Boehringer Ingelheim’s latest investigational treatment ...
People also ask
Is Boehringer Ingelheim developing a gene therapy for cystic fibrosis?
What is Boehringer Ingelheim fibroneer-IPF?
Who is Boehringer Ingelheim?
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program. New treatments are needed to complement existing therapies and to help stop, rather than slow, disease progression.
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis at Boehringer Ingelheim, discusses the unmet needs of patients with IPF and other forms of progressive fibrosing ILDs and the launch of the FIBRONEER™ global clinical program.
May 9, 2023 · Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the...
Oct 26, 2022 · News provided by. Boehringer Ingelheim. Oct 26, 2022, 08:00 ET. Share this article. FIBRONEER ™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational...
May 15, 2022 · Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a Phase III clinical...
Oct 28, 2022 · Boehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF, a Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF).
